Stoke Therapeutics, Inc. has reported significant financial developments in its latest 10-K filing, revealing a substantial increase in revenue and ongoing investments in research and development. For the fiscal year ending December 31, 2025, the company generated $184.4 million in revenue, a notable rise from $36.6 million in the previous year. This increase is primarily attributed to revenue from collaboration agreements with Acadia Pharmaceuticals and Biogen, particularly driven by the performance obligations related to intellectual property licenses and global development activities.
The company's operating expenses also rose, totaling $205 million for 2025 compared to $137.9 million in 2024. Research and development expenses accounted for $137.9 million, up from $89.1 million the previous year, largely due to increased costs associated with the zorevunersen program, which is in late-stage clinical testing for Dravet syndrome. The company is also advancing its second product candidate, STK-002, for the treatment of autosomal dominant optic atrophy (ADOA), which is currently in a Phase 1 study.
Stoke Therapeutics is actively pursuing its strategic goals, including the completion of its Phase 3 EMPEROR study for zorevunersen, which began in May 2025. The company anticipates completing enrollment of approximately 150 patients by mid-2026, with pivotal data expected in mid-2027 to support a New Drug Application (NDA) submission to the FDA. The company has also expanded its capabilities for commercialization in North America and is collaborating with Biogen for development and commercialization outside the U.S., Canada, and Mexico.
As of December 31, 2025, Stoke Therapeutics reported cash, cash equivalents, and marketable securities totaling approximately $390.9 million, which the company believes will fund operations into 2028. However, the company has acknowledged that it has incurred losses since its inception, with a net loss of $6.9 million for 2025, down from $89 million in 2024. The company continues to anticipate ongoing losses as it invests in the development of its product candidates and seeks regulatory approvals. The filing highlights the potential risks and uncertainties associated with product development, regulatory approvals, and market acceptance, which could impact the company's future financial performance.
About Stoke Therapeutics, Inc.
Stoke Therapeutics is a late-stage biotech company developing RNA-based medicines using its proprietary TANGO platform to upregulate protein expression. Focused on severe genetic diseases like Dravet syndrome and ADOA, it designs antisense oligonucleotides to restore normal protein levels, addressing underlying causes. The company collaborates globally for development and commercialization, aiming to deliver disease-modifying therapies for central nervous system and eye disorders.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.